TargetBeta
PPARG
peroxisome proliferator activated receptor gamma · also PPARG1, PPARG2, NR1C3, PPARgamma · Peroxisome proliferator activated receptors
5 programs in company-led studies act on PPARG, from 5 companies: 3 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| saroglitazarrule | Zydus Lifesciences | phase 4 | 196 running | PPARA | ChEMBL |
| Pioglitazonerule | Takeda | phase 4 | 733 running | – | ChEMBL |
| lanifibranor | Inventiva Pharma | phase 3 | 61 running | PPARA, PPARD | the company's pipeline |
| T3D-959rule | T3D Therapeutics | phase 3 | 31 running | PPARD | ChEMBL |
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 90 running | PPARA, PPARD | ChEMBL |
Conditions their studies are in
- Alzheimer Disease, 2 programs
- Diabetes Mellitus, Type 2, 2 programs
- Non-alcoholic Fatty Liver Disease, 2 programs
- Renal Insufficiency, 2 programs
- Diabetes Mellitus, 1 program
- Dyslipidemias, 1 program
- Fatty Liver, 1 program
- Fibrosis, 1 program
- Liver Cirrhosis, Biliary, 1 program
- Peripheral Arterial Disease, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026saroglitazar · Zydus Lifesciences · phase 4 · NCT05045482
- Nov 2027Pioglitazone · Takeda · phase 4 · NCT07848191
- Apr 2031T3D-959 · T3D Therapeutics · phase 3 · NCT06964230
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.